Northern Trust Company of Connecticut’s Celldex Therapeutics CLDX Stock Holding History

Northern Trust Company of Connecticut’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$21K	Buy	+59	New	+$22.7K	﹤0.01%	1986

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

SCA

SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Northern Trust Company of Connecticut's CLDX Position: Q4 2013 in Review

Northern Trust Company of Connecticut opened a new position in Celldex Therapeutics (CLDX) in Q4 2013: 59 shares worth $21K. The stake represents ﹤0.01% of the portfolio and ranks #1986 among its holdings.

162 funds tracked by Wall St. Rank hold CLDX as of Q4 2013.

Northern Trust Company of Connecticut held 59 shares of Celldex Therapeutics worth $21K as of Q4 2013.
Celldex Therapeutics was a new Northern Trust Company of Connecticut position in Q4 2013.
Celldex Therapeutics made up ﹤0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #1986 holding.
162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.